Document:

Exhibit 10.5

                             DRESSER-RAND GROUP INC.
                   GRANT NOTICE FOR 2008 STOCK INCENTIVE PLAN
                            STOCK APPRECIATION RIGHTS

FOR GOOD AND VALUABLE CONSIDERATION, Dresser-Rand Group Inc. (the "Company"),
hereby grants to Participant named below the Stock Appreciation Rights with
respect to the number of shares of its common stock (the "Shares"), that are
covered by the Stock Appreciation Rights, as specified below, at the Exercise
Price per share specified below and upon the terms and subject to the conditions
set forth in this Grant Notice, the Dresser-Rand Group Inc. 2008 Stock Incentive
Plan (the "Plan") and the Standard Terms and Conditions (the "Standard Terms and
Conditions") promulgated under such Plan, each as amended from time to time.
This Stock Appreciation Right is granted pursuant to the Plan and is subject to
and qualified in its entirety by the Standard Terms and Conditions. The Standard
Terms and Conditions may be accessed through Participant's personal Smith-Barney
Benefit Access account in the Plan Documents section.

---------------------------------------------- ---------------------------------
Name of Participant:
---------------------------------------------- ---------------------------------
Social Security Number:
---------------------------------------------- ---------------------------------
Grant Date:
---------------------------------------------- ---------------------------------
Number of Shares of Common Stock covered by
Stock Appreciation Right:
---------------------------------------------- ---------------------------------
Exercise Price Per Share:                      $
---------------------------------------------- ---------------------------------
Expiration Date:
---------------------------------------------- ---------------------------------
Vesting Schedule:
---------------------------------------------- ---------------------------------

By accepting this Grant Notice, Participant acknowledges that he or she has
received and read, and agrees that these Stock Appreciation Rights shall be
subject to, the terms of this Grant Notice, the Plan and the Standard Terms and
Conditions.

DRESSER-RAND GROUP INC.
                                          --------------------------------------
                                                   Participant Signature
By
       ------------------------------
Title:                                    Address (please print):
       ------------------------------

                                          --------------------------------------

                                          --------------------------------------

                                          --------------------------------------

<PAGE>

                             DRESSER-RAND GROUP INC.
                        STANDARD TERMS AND CONDITIONS FOR
                            STOCK APPRECIATION RIGHTS

These Standard Terms and Conditions apply to any Stock Appreciation Rights (the
"SARs") granted under the Dresser-Rand Group Inc. 2008 Stock Incentive Plan (the
"Plan"), which are evidenced by a Grant Notice or an action of the Committee
that specifically refers to these Standard Terms and Conditions.

1.    TERMS OF STOCK APPRECIATION RIGHTS

      Dresser-Rand Group Inc. (the "Company"), has granted to the Participant
      named in the Grant Notice provided to said Participant herewith (the
      "Grant Notice") Stock Appreciation Rights with respect to the number of
      shares of the Company's common stock (the "Shares"), set forth in the
      Grant Notice, at the purchase price per share and upon the other terms and
      subject to the conditions set forth in the Grant Notice, these Standard
      Terms and Conditions (as amended from time to time), and the Plan. For
      purposes of these Standard Terms and Conditions and the Grant Notice, any
      reference to the Company shall include a reference to any Subsidiary.

2.    EXERCISE OF STOCK APPRECIATION RIGHT

      The Stock Appreciation Right shall not be exercisable as of the Grant Date
      set forth in the Grant Notice. After the Grant Date, to the extent not
      previously exercised, and subject to termination or acceleration as
      provided in these Standard Terms and Conditions and the Plan, the Stock
      Appreciation Right shall be exercisable to the extent it becomes vested,
      as described in the Grant Notice. The Participant may exercise any SARs
      that have become vested and exercisable by providing written notice of
      exercise to the Company specifying the number of SARs to be exercised. As
      soon as practicable following receipt of notice of exercise, the Company
      shall make a payment to the Participant equal to the excess of (i) the
      aggregate Fair Market Value on the date of exercise of the number of
      Shares subject to the SARs being exercised over (ii) the aggregate
      Exercise Price of the SARs being exercised. Such payment shall be made in
      cash, in Shares or in a combination thereof, as determined by the
      Committee in its sole discretion.

      Fractional shares may not be exercised. To the extent payment is in the
      form of Shares of Common Stock, such Shares of Common Stock will be issued
      as soon as practical after exercise. Notwithstanding the above, the
      Company shall not be obligated to deliver any shares of Common Stock
      during any period when the Company determines that the exercisability of
      the SAR or the delivery of Shares hereunder would violate any federal,
      state or other applicable laws.

<PAGE>

3.    EXPIRATION OF STOCK APPRECIATION RIGHTS

      Except as provided in this Section 3, the Stock Appreciation Rights shall
      expire and cease to be exercisable as of the Expiration Date set forth in
      the Grant Notice.

      A.    If the Participant's employment terminates by reason of death or
            Disability, the Participant (or the Participant's estate,
            beneficiary or legal representative) may exercise the Stock
            Appreciation Rights (regardless of whether then vested or
            exercisable) until the earlier of (1) the twelve-month anniversary
            of the date of such termination of employment and (2) the Expiration
            Date.

      B.    If the Participant's employment terminates for any reason other than
            death, Disability or Cause, the Participant may exercise any Stock
            Appreciation Rights that are vested and exercisable at the time of
            such termination of employment until the earlier of (A) the 90-day
            anniversary of the date of such termination of employment and (B)
            the Expiration Date. Any portion of the Stock Appreciation Rights
            that is not vested and exercisable at the time of such a termination
            of employment shall be forfeited and canceled as of the date of
            termination of employment.

      C.    If the Participant's employment is terminated for Cause, the entire
            Stock Appreciation Rights, whether or not then vested and
            exercisable, shall be immediately forfeited and canceled as of the
            date of such termination of employment.

4.    CHANGE IN CONTROL

      Unless otherwise provided in an employment, severance or other agreement
      between the Company and the Participant, the Committee shall determine the
      effect of a Change in Control on the Stock Appreciation Rights. Without
      limitation, the Committee may provide for the acceleration of vesting and
      exercisability of any unvested Stock Appreciation Rights, for a cash
      payment based on the Change in Control Price in settlement of the Stock
      Appreciation Rights, or for the assumption or substitution of Stock
      Appreciation Rights by the Participant's employer (or the parent or an
      Affiliate of such employer) that engages the Participant immediately
      following the Change in Control.

5.    RESTRICTIONS ON RESALES OF SHARES

      The Company may impose such restrictions, conditions or limitations as it
      determines appropriate as to the timing and manner of any resales by the
      Participant or other subsequent transfers by the Participant of Shares (if
      any) issued as a result of the exercise of the Stock Appreciation Right,
      including without limitation (a) restrictions under an insider trading
      policy, (b) restrictions designed to delay and/or coordinate the timing
      and manner of sales by Participant and other holders of stock appreciation
      rights and/or stock options and (c) restrictions as to the use of a
      specified brokerage firm for such resales or other transfers.

                                       2
<PAGE>

6.    INCOME TAXES

      The Company shall not deliver cash or shares of Common Stock in respect of
      the exercise of any Stock Appreciation Right unless and until the
      Participant has made arrangements satisfactory to the Committee to satisfy
      applicable withholding tax obligations. Unless otherwise permitted by the
      Committee, withholding shall be effected by withholding amounts payable
      (including, to the extent applicable, Shares of Common Stock) issuable in
      connection with the exercise of the Stock Appreciation Rights. The
      Participant acknowledges that the Company shall have the right to deduct
      any taxes required to be withheld by law in connection with the exercise
      of the Stock Appreciation Rights from any amounts payable by it to the
      Participant (including, without limitation, future cash wages).

7.    NON-TRANSFERABILITY OF STOCK APPRECIATION RIGHTS

      The Participant may not assign or transfer the Stock Appreciation Right to
      anyone other than by will or the laws of descent and distribution and the
      Stock Appreciation Right shall be exercisable only by the Participant
      during his or her lifetime. The Company may cancel the Participant's Stock
      Appreciation Right if the Participant attempts to assign or transfer it in
      a manner inconsistent with this Section 7.

8.    THE PLAN AND OTHER AGREEMENTS

      In addition to these Terms and Conditions, the Stock Appreciation Rights
      shall be subject to the terms of the Plan, which are incorporated into
      these Standard Terms and Conditions by this reference. Capitalized terms
      not otherwise defined herein shall have the meaning set forth in the Plan.

      The Grant Notice, these Standard Terms and Conditions and the Plan
      constitute the entire understanding between the Participant and the
      Company regarding the Stock Appreciation Rights. Any prior agreements,
      commitments or negotiations concerning the Stock Appreciation Rights are
      superseded.

9.    LIMITATION OF INTEREST IN SHARES SUBJECT TO SARS

      Neither the Participant (individually or as a member of a group) nor any
      beneficiary or other person claiming under or through the Participant
      shall have any right, title, interest, or privilege in or to any shares of
      Common Stock allocated or reserved for the purpose of the Plan or subject
      to the Grant Notice or these Standard Terms and Conditions except as to
      such shares of Common Stock, if any, as shall have been issued to such
      person upon exercise of the Stock Appreciation Rights or any part of it.
      Nothing in the Plan, in the Grant Notice, these Standard Terms and
      Conditions or any other instrument executed pursuant to the Plan shall
      confer upon the Participant any right to continue in the Company's employ
      or service nor limit in any way the Company's right to terminate the
      Participant's employment at any time for any reason.

                                       3
<PAGE>

10.   GENERAL

      In the event that any provision of these Standard Terms and Conditions is
      declared to be illegal, invalid or otherwise unenforceable by a court of
      competent jurisdiction, such provision shall be reformed, if possible, to
      the extent necessary to render it legal, valid and enforceable, or
      otherwise deleted, and the remainder of these Standard Terms and
      Conditions shall not be affected except to the extent necessary to reform
      or delete such illegal, invalid or unenforceable provision.

      The headings preceding the text of the sections hereof are inserted solely
      for convenience of reference, and shall not constitute a part of these
      Standard Terms and Conditions, nor shall they affect its meaning,
      construction or effect.

      These Standard Terms and Conditions shall inure to the benefit of and be
      binding upon the parties hereto and their respective permitted heirs,
      beneficiaries, successors and assigns.

      These Standard Terms and Conditions shall be construed in accordance with
      and governed by the laws of the State of Delaware, without regard to
      principles of conflicts of law.

      All questions arising under the Plan or under these Standard Terms and
      Conditions shall be decided by the Committee in its total and absolute
      discretion.

12.   ELECTRONIC DELIVERY

      By executing the Grant Notice, the Participant hereby consents to the
      delivery of information (including, without limitation, information
      required to be delivered to the Participant pursuant to applicable
      securities laws) regarding the Company and the Subsidiaries, the Plan, the
      Stock Appreciation Rights and the Common Stock via Company web site or
      other electronic delivery.

                                       4Exhibit
      10.1

    LICENSE
      AGREEMENT

    

    Made
      this
      20th
      day of
      January 2008 (the "Effective
      Day"),
      by
      and between Synvista, with its principal place of business at
      ______________________________________________________________________________
      (hereinafter the "Company")
      and
      Novel Therapeutic Technology Inc with its principal place of business at POB
      12006, 7 Yad Harutzim, Herzliya Pituach 46722 ISRAEL (hereinafter "NTT");

    

    WHEREAS,
      NTT has
      sole and exclusive rights under an Exclusive License Agreement (the
      "Yissum
      Agreement")
      from
      Yissum Research Development Company of the Hebrew University of Jerusalem
      ("Yissum"),
      for
      drug delivery technology known as the ETHOSOMETM Delivery System know-how and
      formulations using such delivery system ("Ethosome")
      , and
      is able and willing to enter into a licensing agreement with the Company for
      Ethosome and the formulation of a drug of the Company using the Ethosome
      formulation technology,

    

    WHEREAS,
      the
      Company is the exclusive licensee of the rights in and to certain organoselenium
      Drug as further detailed below; and 

    

    WHEREAS,
      The
      Company wishes to obtain a license from NTT and NTT wishes to grant a license
      to
      the Company for the Product (as hereinafter defined), Drug Formulation (as
      defined hereinafter), Development Results (as hereinafter defined), Resulting
      Patents (as hereinafter defined), NTT Patents (as hereinafter defined) and
      NTT
      Formulation Technology (as hereinafter defined), subject to the terms
      and

    

    conditions
      of this Agreement

    

    NOW
      THEREFORE THE PARTIES DO HEREBY AGREE AS FOLLOWS:

    

    1. Interpretation
      and Definitions

    

    1.1 The
      preamble and appendices annexed to this Agreement constitute an integral part
      hereof and shall be read jointly with its terms and conditions.

    

    1.2 In
      this
      Agreement, unless otherwise required or indicated by the context, the singular
      shall include the plural and vice-versa,
      the
      masculine gender shall include the female gender, and the use of the word "or"
      means "and/or”.

    

    1.3 The
      headings of the sections in this Agreement are for the sake of convenience
      only
      and shall not serve in the interpretation of the Agreement.

    

    
      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

    

    

    1.4
       In
      this
      Agreement, the following capitalized terms shall have the meanings appearing
      alongside them, unless provided otherwise:

    

    1.4.1 "Affiliate"
      means
      any person or organization controlling, controlled by or under common control
      with the Company, including any parent, subsidiary or affiliate company. The
      term "control" means direct or indirect ownership of more than fifty percent
      50%
      of the outstanding stock or other voting interest, entitled to vote for the
      election of a majority of directors or to direct the management and policies
      of
      any party, directly or indirectly.

    

    1.4.2 "Agreement"
      means
      this agreement together with all the appendices and annexes hereto.

    

    1.4.3 "Company
      Confidential Information"
      means
      the Drug and all technical, scientific and commercial information including
      but
      not limited to any data, trade secrets, know-how, assays, materials,
      formulations, solubility, stability, analytical methods, compositions, reports,
      notebooks, certificates, regulatory information, authorizations, approvals,
      synthesis, materials, methods, results, and/or processes, of the Company; which
      either are disclosed by the Company, or, resulting from use of the Drug and
      are
      directly related thereto, whether disclosed orally, in writing or
      electronically. Company Confidential Information shall not include the Drug
      Formulation.

    

    1.4.4 "Development
      Plan"
      means
      the written plan, and any amendments thereof, attached hereto as Exhibit
      A,
      which
      sets forth the development of Drug Formulation. 

    

    1.4.5 "Development
      Results"
      means:
      i) the Product; ii) Drug Formulation; iii) any and all data, information,
      experiments, trade secrets, know-how, assays, solubility, stability, analytical
      methods, compositions, derivatives, synthesis, materials, results, and/or
      processes; and certificates, authorizations, approvals, reports, which results
      from, or arises under the Development Plan; and iv) any and all conceptions,
      inventions arising under or resulting from the Development Plan; and/or claim
      or
      disclose the Product, Drug Formulation except for Intellectual Property Rights
      of NTT and Company existing prior to the Effective Date.

    

    1.4.6 "Drug"
      means
      the Company's organoselenium drug or materials, as specified in Exhibit
      B
      hereto,
      and its racemate, metabolite, derivatives, isomers, polymorphs,
      crystals.

    

    1.4.7 "Drug
      Formulation"
      means
      the formulation of the Drug utilizing NTT's Formulation Technology.

    

    1.4.8 "First
      Commercial Sale"
      means,
      with respect to any country, the first bona fide arm's-length sale of the
      Product in such country following receipt of all regulatory approvals necessary
      to commence regular, commercial scale sales of the Product in such country,
      excluding, however, any sale or other distribution for use in a clinical trial.
      Any sale prior to receipt of all approvals necessary to commence commercial
      sales, such as any so-called "named patient sale" or "compassionate use" sale,
      shall not be deemed a First Commercial Sale.

    

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

        
        

      

      
        2

        
          

        

      

      
        
        

      

    

     

    "Intellectual
      Property Rights"
      shall
      mean any and all patents and patent applications and the rights in such patents,
      in the Territory, including any and all divisionals, continuations,
      continuations-in-part, reissues, renewals, substitutions, registrations,
      re-examinations, revalidations, extensions, supplementary protection
      certificates, pediatric exclusivity periods and the like of any such patents
      and
      patent applications, and foreign equivalents

    

    "Intercompany
      Consideration"
      means
      consideration received by the Company and its Affiliates from among the Company
      and its Affiliates.

    

    "License"
      means
      the license granted by NTT to the Company under Section 3.1
      hereto.

    

    1.4.9 "Net
      Sales"
      means
      the gross amount invoiced for sales of Product by or on behalf of the Company,
      its Affiliates or Sublicensees to any third party (whether an end-user, or
      a
      distributor), exclusive of Inter-Company transfers or sales to or from
      Affiliates or Sublicensees, less the following deductions from such gross
      amounts only to the extent reasonable and customary, and which are actually
      incurred and included in gross amounts invoiced (i) all discounts, returns,
      rejections and retroactive price reductions given in respect of such sales
      and
      credits or allowances actually paid or granted, (ii) deducting sales, excise
      and
      similar taxes (including VAT) or other relevant governmental charges, and (iii)
      transportation, packaging and insurance charges; amounts actually credited,
      rebated or allowed for rejections or returns of Product; retroactive price
      reductions that are actually allowed or granted, bad debt, transportation
      expenses related to the sale of Product and custom duties imposed and with
      reference to the sale of Product. Such deductions shall be directly related
      to
      the sale of Products that were awarded within the regular running of the
      business of the Company and made at "arms length". In the event of sales not
      made at "arms length", Net Sales shall be calculated in accordance with the
      current market conditions, or in the absence of such conditions, according
      to
      reasonable conditions for such sale. 

    

    1.4.10 "NTT
      Confidential Information"
      means
      the NTT Formulation Technology, the Ethosome Drug Delivery System, as defined
      below, and all technical, scientific and commercial information including but
      not limited to any data, trade secrets, know-how, assays, materials,
      formulations, solubility, stability, analytical methods, compositions, reports,
      notebooks, certificates, regulatory information, authorizations, approvals,
      synthesis, materials, methods, results, and/or processes, of NTT; whether
      disclosed orally, in writing or electronically.

    

    
      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

          
          

        

        
          3

          
            

          

        

        
          
          

        

      

    

    

    1.4.11 "NTT
      Formulation Technology"
      means a
      drug delivery technology and know-how, information, trade secrets and NTT
      Patents in formulations of drugs known as the ETHOSOMETM
      Drug
      Delivery System "(Ethosome") 

    

    1.4.12 "NTT
      Patents"
      shall
      mean the patents and/or patent applications covering or disclosing NTT
      Formulation Technology; and including but not limited to, U.S. Patent No. [***],
      U.S. Patent No. [***] and PCT International Application No. [***] and any
      continuations, continuations-in-part, extensions, divisions, substitutions
      or
      additions to such applications and all patents which are reissues thereof,
      re-validations and registrations based thereon, and any and all foreign patents
      and patent applications corresponding thereto.

     

    1.4.13 "Party"(
      collectively: the "Parties")
      means
      each of the Company and NTT.

     

    1.4.14
      "Product"
      means a
      pharmaceutical preparation or composition containing the Drug Formulation which
      is covered by a Valid Patent Claim.

    

    1.4.15 "Regulatory
      Approval"
      means
      any approvals (including supplements, amendments, pre- and post-approvals and
      price approvals), licenses, registrations or authorizations of any national,
      supra-national (e.g., the European Commission or the Council of the European
      Union), regional, state or local regulatory agency, department, bureau,
      commission, council or other governmental entity, necessary for the manufacture,
      distribution, or sale of Products in a regulatory jurisdiction.

    

    1.4.16
      "Reporting
      Period"
      means,
      with respect to the Product in any country in the Territory, on a bi-annual
      basis, commencing with the First Commercial Sale of such Product in such country
      and ending upon termination of the this Agreement. 

    

    1.4.17 "Resulting
      Patents"
      means
      patents and patent applications and the rights in such patents, in the
      Territory, including any and all divisionals, continuations,
      continuations-in-part, reissues, renewals, substitutions, registrations,
      re-examinations, revalidations, extensions, supplementary protection
      certificates, pediatric exclusivity periods and the like of any such patents
      and
      patent applications, and foreign equivalents of the foregoing that incorporate
      information or results arising under or resulting from the Development Plan,
      and/or claim or disclose the Product, Drug Formulation; except for Intellectual
      Property Rights of NTT and Company existing prior to the Effective
      Date.

    

    
      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

          
          

        

        
          4

          
            

          

        

        
          
          

        

      

    

    

    1.4.18 "Sublicensee"
      shall
      mean the granting or licensing of any rights to a third party by the Company
      or
      its Affiliates to make, commercialize, use, sell and/or import (except where
      the
      implied right to use accompanies the sale to the third party end user the
      Product by the Company or its Affiliates or Sublicensees).

    

    1.4.19 "Sub-License
      Consideration"
      means
      the consideration received by the Company for the granting of a Sublicense.
      Notwithstanding the foregoing, Sublicense Consideration shall not include:
      i)
      consideration received by the Company and its Affiliates from among the Company
      and its Affiliates ("Intercompany
      Consideration");
      and
      ii) payments made to the Company by a licensee for research and development
      expenses directly related to the Products as defined by FASB accounting; iii)
      payments made to the Company by a licensee for any equity investment or
      financing at a price per share (or other security or debt, warrant of other
      financial instrument) equal to or lower than the market value of such shares
      (or
      other securities).

    

    1.4.20 "Territory"
      means
      worldwide.

    

    1.4.21 "Valid
      Patent Claim"
      shall
      mean a claim of an issued and unexpired patent, including those with an extended
      term under patent term adjustment, patent term extension or pediatric
      exclusivity claiming the Drug or Drug Formulation, including NTT Patents and
      Resulting Patents, which would be infringed by the unauthorized sale or use
      of
      the Product in the country of sale, which claim has not been revoked or held
      unenforceable or invalid by a decision of a court or other governmental agency
      of competent jurisdiction (which decision is no longer appealable), and which
      claim has not been disclaimed, denied or admitted to be invalid or unenforceable
      through reissue, re-examination or disclaimer or otherwise (including such
      claim
      during the term of any statutory or regulatory exclusivity periods that relate
      back to or apply to that claim).

    

    2. Development
      Plan

    

    2.1 Performance
      NTT will
      use its reasonable efforts to perform the Development Plan in accordance with
      the timetable set forth therein. Performance of the Development Plan will be
      subject to the Company's provision to NTT such information regarding suggested
      Drug concentrations and any relevant data requested by NTT as set forth in
      the
      Development Plan. NTT shall provide personnel, facilities, and resources as
      required to accomplish the work necessary to complete and accordance with the
      Project. NTT shall retain separate laboratory data books and notebooks for
      any
      and all data, results, experiments, and information of the Development Results;
      copies of all such records shall be provided to Company upon Company's written
      request. NTT shall not co-mingle Drug or Company Confidential Information with
      that of a third party; or with any NTT Formulation Technology of NTT not under
      this Agreement.

    NTT,
      upon
      written request from the Company, and/or upon Termination, shall provide to
      Company a detailed Report. In addition, NTT shall provide such additional
      periodic written reports or attend such additional meetings with Company as
      Company shall determine are necessary with respect to the status of NTT's
      activities under this Agreement and the Project, at the Company 's expense
      and
      on reasonable notice from Company. NTT shall conduct regular telephone
      conferences and no less frequently than once every two weeks with Company to
      discuss the details, results and progress of the Development Plan.

    NTT
      expressly disclaims any and all implied or express warranties pertaining to
      the
      Development Results and makes no express or implied warranties of
      merchantability, fitness for any particular purpose of the Development Results,
      chemical stability, toxicology and/or tolerability thereof.

    
      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

          
          

        

        
          5

          
            

          

        

        
          
          

        

      

    

    

    2.2 Compliance.
      In
      carrying out the Development Plan, NTT agrees that if applicable it will comply
      with all generally accepted standards of Good Laboratory practices and all
      applicable local, state and federal laws. 

    

    2.3 Regulatory
      Cooperation.
      NTT
      shall cooperate with US and European regulatory authorities, and allow them
      access to NTT's facilities and premises and to records and data that are
      relevant for the Development Plan. Each Party shall promptly inform the other
      Party of any request or effort by any such regulatory authority to review
      records and data, or to contact, visit, or inspect NTT or NTT's records and
      data, relating to the Development Plan, and shall notify the other Party within
      two (2) business days, or as reasonably practicable, if any regulatory authority
      issues or gives any notice of intent to inspect, notice of inspection, notice
      of
      inspectional observations, warning letter, or other written communication
      concerning the Development Plan. The Company shall have the sole right and
      responsibility with respect to interactions with regulatory authorities
      regarding the development, marketing, sale and/or manufacturing of Products,
      including but not limited to any IND, marketing authorization. Each party agrees
      to notify (the "Notifying Party") the other party within two (2) working days
      of
      any information of which the Notifying Party becomes aware concerning any side
      effect, injury, toxicity or sensitivity reaction, or any unexpected incident,
      and the severity thereof, whether or not determined to be attributable to any
      NTT Formulation Technology, Drug Formulation, and/or Product (hereinafter
      "Adverse
      Experience"),
      where
      such Adverse Experience is (i) serious and associated with the clinical uses,
      studies, investigations, tests and marketing of Product, whether or not
      determined to be attributable to Product. With respect to all other adverse
      experiences (non-serious expected or non-serious unexpected adverse
      experiences), the Notifying Party shall furnish the other party with copies
      of
      such non-serious adverse experiences in connection with the marketing of Product
      within 10 working days after receipt. "Serious" as used in this Section refers
      to an experience which results in death, is immediately life threatening,
      results in persistent and significant disability/incapacity or requires
      in-patient hospitalization, or prolongation of existing hospitalization, or
      is a
      congenital anomaly, cancer or an overdose. Other important medical events that
      may jeopardize the patient or may require intervention to prevent one of the
      outcomes previously listed should also be considered serious. "Unexpected"
      as
      used in this Section refers to a condition or development not listed in the
      current labeling for Product, and includes an event that may be symptomatically
      and pathophysiologically related to an event listed in the labeling, but differs
      from the event because of increased frequency or greater severity or
      specificity. Furthermore, each party agrees throughout the Term to notify the
      Company of any "Serious" Adverse Experience which occurs in the Territory within
      2 working days after the Notifying Party becomes aware of such event and of
      any
      Non-serious Adverse Experience which occurs in the Territory within 10 working
      days after the Notifying Party becomes aware of such event.

    

    
      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

          
          

        

        
          6

          
            

          

        

        
          
          

        

      

    

    

    2.4 Company's
      Information and License.
      The
      Company will provide NTT, Drug and related know how as set forth in the
      Development Plan ("Company's
      Information").
      The
      Company hereby grants NTT the right to use the Company's Information solely
      for
      conducting the Development Plan. NTT may not use the Drug or Company
      Confidential Information for any other purpose. Any information, data, results,
      know, how, materials, derivatives, methods, and/or composition related directly
      to the Drug resulting from the Development Plan, and which is not the Drug
      Formulation, shall be solely and exclusively owned by the Company ("New
      Company Information”),
      and
      NTT has not rights to use. Upon termination of this Agreement, NTT shall have
      no
      use right under this Section. 

    

    
      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

          
          

        

        
          7

          
            

          

        

        
          
          

        

      

    

    

    2.5 Changes
      to the Development Plan.
      Any
      variation of the Development Plan must be agreed in writing by NTT and
      Company.

    

    2.6 Limitation
      on Use.
      NTT
      will not use the Drug, Product, Drug Formulation, Development Results,
      Intellectual Property Rights including Resulting Patents that result from the
      Development Plan and/or Development Results, Company Confidential Information
      for any purpose other than as explicitly set forth in this Agreement. Upon
      termination or completion of the Development Plan, all Company Confidential
      Information, Drug shall be returned to Company or destroyed at Company's sole
      option and at Company's expense. However, nothing herein shall affect NTT's
      rights to use NTT's Formulation Technology for any purpose, including
without
      limitation, for the purpose of other drugs formulation.

    

    2.7 NTT
      shall
      provide to the Company at Termination and/or upon written request from the
      Company, a detailed Report including the Developmental Results. In addition,
      NTT
      shall provide such additional periodic written reports or attend such additional
      meetings with Company as Company shall determine are necessary with respect
      to
      the status of NTT's activities under the Development Plan, at the Company's
      expense and on reasonable notice from Company.

    

    2.8 At
      the
      expiration or termination of this Agreement, and subject to the provisions
      of
      Section 8A below, (i) all Drug, and (ii) any materials, information, databases
      and records, accounts, notes, reports and data obtained or generated by NTT
      in
      the course of providing services under this Agreement, which constitute Company
      Confidential Information, and (iii) any Development Plan Results which
      constitute New Company Information, shall, at Company's option and at its
      direction and written request, and wherever reasonably practicable, and subject
      to the provisions of Section 8.1 below be (a) delivered to Company at its
      offices in such form(s) as Company shall request, (b) retained by NTT in
      accordance with applicable law, regulation, and NTT policy, or (c) disposed
      of,
      unless NTT is otherwise required to retain such materials, information,
      databases and records, accounts, notes, reports or data, or copies thereof,
      under applicable law or regulations. All costs of delivering the same to
      Company, including without limitation shipping costs, or of disposing or
      retaining the same shall be borne by Company.

    

    
      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

          
          

        

        
          8

          
            

          

        

        
          
          

        

      

    

    

    3. Grant
      of License by NTT

    

    3.1 Grant
      of License.
      NTT
      hereby grants to the Company an exclusive worldwide through multiple tier
      license, in the Territory, to: 1) the Intellectual Property Rights resulting
      from and/or arising under the Development Plan and/or Development Results
      including Resulting Patents, and/or the Drug Formulation and/or Product ; and
      2)
      to make, have made, use, have used and/or license the Drug Formulation and/or
      the Development Results, and 3) to make, have made, sell, have sold, use, have
      used, license, and/or import Product; and 4) an exclusive license in the
      Territory to any Patents covering the Drug Formulation and Product to enable
      the
      Company to make, have made, sell, have sold, and/or use Products. The Company
      shall not use the Drug Formulation and/or the Development Results for any
      purpose other than exercise of the License. NTT hereby grants to the Company
      a
      non-exclusive license, in the Territory under the NTT Patents, to use the NTT
      Formulation Technology to 1) develop, make, have made, and use, the Drug
      Formulation, and 2) develop, make, have made, sell, have sold, and use,
      Product.

    

    No
      Implied Licenses.
      Except
      as explicitly set forth in this Agreement, neither Party shall acquire any
      license or other intellectual property interest, by implication or otherwise,
      in
      any proprietary information disclosed to it under this Agreement or under any
      trademarks, patents or patent applications owned or controlled by the other
      Party or its Affiliates.

    

    3.2 Rights
      to Sublicense.
      The
      Company shall have the right to grant sublicenses, through multiple tiers of
      sublicenses, provided that ally such sublicense shall expressly provide for
      the
      Sublicensee to be bound by obligations consistent with those provided in this
      Agreement.

    

    The
      Company shall provide NTT with prompt written notice of each sublicense
      agreement, as well as a copy of such sublicense agreement; provided that the
      Company may redact from such copy any terms not necessary to confirm compliance
      with this Agreement.

    

    3.3 Term
      of the License.

    

    The
      License shall commence on the effective day and shall end, if not ended or
      terminated prior thereto pursuant to the provisions hereof, at the earlier
      of
      the following:

    

    
      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

          
          

        

        
          9

          
            

          

        

        
          
          

        

      

    

    

    (a)
      the
      date the Company notifies NTT that the Company does not intend to proceed with
      further development of the Drug Formulation, such notice to be made promptly
      after the Company makes such determination; or

    

    (b)
      the
      date the Company notifies NTT that the Company does not intend to continue
      to
      commercialize Product(s) based upon NTT Formulation Technology, such notice
      to
      be made promptly after the Company makes such determination; or

    

    (c)
      The
      later to occur of (i) date of expiration of the last valid registered NTT Patent
      or Resulting Patent in the Territory upon which the Product, absent the License,
      would infringe any Valid Patent Claim included in the registered NTT Patents
      and/or Resulting Patent, or any portion thereof, and (ii) the end of a period
      of
      15 years from the date of making the First Commercial Sale pursuant to the
      License.

    

    4. Consideration
      and Reporting.

    

    4.1 License-fee
      milestone payments.
      In
      consideration for the rights granted herein to the Company, the Company will
      make the following non-refundable license-fee milestone payments to
      NTT:

     

    
      	
              Milestone

            	 	
              Payment (in US Dollars)

            
	 	 	 
	
              Within 5 days
                following the Effective Date

            	 	
              [***]

            
	 	 	 
	
              90
                days from the Effective Day

            	 	
              [***]

            
	 	 	 
	
              The
                earliest of (a) within 30 days of the first enrollment in any country
                of
                the first patient in a Phase III clinical trial study (or equivalent
                clinical program outside of the United States) or, (b) 36 months
                from
                Effective Day.

            	 	
              [***]

            
	 	 	 
	
              The
                earliest of (a) Within 30 days of first received Regulatory Approval
                or,
                (b) 72 months form the effective day.

            	 	
              [***]

            

    

     

    4.2
      Royalties.
      In
      addition to the fees set forth in Section 4.1 above, in consideration of the
      rights granted to the Company by NTT hereunder, for sales of the Product by
      the
      Company, its Affiliates and Sublicensees, the Company shall pay to NTT a [***]%
      royalty on Net Sales of the Product. No royalty shall accrue under this Section
      4.2 on sales among the Company, its Affiliates and Sublicensees, unless the
      Company or such Affiliate or Sublicensee is the end user of a
      Product.

     

    
      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

          
          

        

        
          10

          
            

          

        

        
          
          

        

      

    

    

    4.3 Sub-License
      Fee.
      As
      additional consideration for the license granted to the company the Company
      shall pay NTT a Sub-License Fee of [***] percent ([***] %) of all Sub-License
      Consideration for rights in the Drug Formulation or Product by Sublicensee.
      Any
      consideration paid to a third party for a license to patents covering the Drug
      Formulation or Products, shall, in the event necessary to enable the
      commercialization of the Product and related to NTT Formulation Technology,
      and
      subject to NTT's consent to such sub-license, which will not be unreasonably
      withheld or delayed, be credited against the Royalties and Sub-License Fees
      due
      to NTT. 

    

    4.4 Reporting.
      Ten (10)
      days after the end of each Reporting Period, the Company shall furnish NTT
      with
      a report (herein "Periodic
      Report")
      detailing the total sales effected during the Reporting Period and the total
      Royalties due to NTT in respect of that period (each, a "Royalty
      Period").
      The
      Periodic Reports shall contain full particulars of all sales made by the Company
      and/or Sub-Licensees and all of the proceeds obtained by the Company in respect
      of granting Sub-Licenses, including sales broken down according to countries,
      a
      breakdown of the number of Products sold, discounts, returns, the currency
      in
      which the sales were made, invoice date and all other relevant information
      enabling the Royalties and Sub-License Consideration payable to be calculated.
      The Periodic Reports shall also specify any sale to an Affiliate and shall
      set
      forth full details thereof.

    

    4.5 Terms
      of Payment.
      On the
      date prescribed for the submission of each Periodic Report, the Company shall
      pay the Royalties due to NTT in accordance with the Periodic Report; provided
      that, for royalties due to NTT with respect to Net Sales of Products by the
      Company's Sublicensees, such payment shall be due within the 30 days after
      the
      Company receives such royalties from such Sublicensee, but in no event later
      than 60 days after the end of such calendar quarter.

    

    All
      amounts payable under this Section will first be calculated in United Stated
      dollars after converted from the currency of sale. The buying rates involved
      for
      the currency of the United States into which the currencies involved are being
      exchanged shall be the arithmetic averages of the ones quoted by the Western
      Edition of The Wall Street Journal at the close of business on the last business
      day of each calendar month of the applicable Royalty Period. In the event that
      such publication no longer publishes such rates, another financial publication
      mutually agreed on by the Parties shall be substituted.

    

    
      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

          
          

        

        
          11

          
            

          

        

        
          
          

        

      

    

    

    4.6 Payments
      by the Company to NTT.
      All
      payments due under this Agreement shall be payable in United States dollars.
      The
      Company shall make all payments to NTT by bank wire transfer in immediately
      available funds, or as otherwise specified by NTT in writing.

    

    4.7 Records.
      The
      Company and its Affiliates shall maintain complete and accurate records of
      the
      Product made, used or sold by them or their Sublicensees under this Agreement,
      and any amounts payable to NTT in relation to the Product, which records shall
      contain sufficient information to NTT to confirm the accuracy of any reports
      delivered to them in accordance with Section 4. The Company and its Affiliates
      shall retain such records relating to a given Royalty Period for at least two
      (2) years after the conclusion of that Royalty Period.

    

    4.8 Audit
      Rights.
      NTT
      (acting as the "Auditing
      Party")
      shall
      have the right, at its own expense, to cause an independent certified public
      accountant reasonably acceptable to the Company, to inspect such records of
      the
      Company or its Affiliates (the "Audited
      Party")
      during
      normal business hours for the sole purpose of verifying any reports and payments
      delivered under this Agreement. Such accountant shall be bound by a
      confidentiality agreement, and shall not disclose to the Auditing Party any
      information other than information relating to accuracy of reports and payments
      delivered under this Agreement and shall provide the Audited Party with a copy
      of any report given to the Auditing Party. The Parties shall reconcile any
      underpayment or overpayment within 30 days after the accountant delivers the
      results of the audit. The Auditing Party shall bear the full cost of the audit
      unless the audit performed under this Section reveals an underpayment in excess
      of [***]% in any Royalty Period, in which case the Audited Party shall bear
      the
      full cost of such audit. NTT may exercise its rights under this Section no
      more
      than once every calendar year and only with reasonable prior notice to the
      Company. The Company shall require that its Affiliates and its Sublicensees
      shall have the obligation to account and provide records to the Company for
      all
      their sales of Products as annual Net Sales by the Company.

    

    4.9 Late
      Payments.
      In the
      event that any payment, including royalty payments, due hereunder is not made
      within 30 days of receiving written notice of the date due, the payment shall
      accrue interest from that date due at the rate of [***]% per
      month.

    

    
      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

          
          

        

        
          12

          
            

          

        

        
          
          

        

      

    

    

    4.10 Taxes.
      Payment
      of Value Added Tax (if charged) shall be added to each payment in accordance
      with the statutory rate in force at such time. NTT shall pay any and all taxes
      levied on account of royalties and other payments it receives under this
      Agreement. If laws or regulations require that taxes be withheld, the Company
      will deduct such taxes from the amount due to NTT, pay such taxes to the proper
      tax authority, and send evidence of the obligation together with proof of
      payment to NTT promptly after making such payment.

    

    4.11 The
      provisions of this Section 4 are material terms of the Agreement and the breach
      thereof shall constitute a material breach of the Agreement.

    

    5. Development
      and Commercialization 

    

    5.1 Development
      and Commercialization.
      The
      Company shall use commercially reasonable efforts to develop and commercialize
      the Product. The Company undertakes, at its own expense, to carry out the
      regulatory work necessary to receive regulatory approval for the Product in
      a
      timely manner. 

    

    5.2 Development
      Reporting.
      The
      Company shall provide NTT with bi-annual reports, which shall proved a timeline
      and description of the clinical studies to be conducted or which are in progress
      during the six months prior to the report. Such report shall also set forth
      a
      general assessment regarding the completion date of the development of the
      Product and the marketing thereof.

    

    6.
      Ownership

    

    6.1 Ownership
      by the Company.
      All
      rights to the Drug, and Company Confidential Information and New Company
      Information shall be solely and exclusively owned by the Company, and no right,
      title, and/or interest is granted, licensed, transferred, conveyed implicitly
      or
      explicitly to NTT.

    

    6.2 Ownership
      by NTT.
      All
      rights in the NTT Formulation Technology, Drug Formulation, Development Results
      and Resulting Patents, except for the New Company Information, and all NTT
      Patents and all NTT Confidential Information shall, as between the Parties,
      be
      solely owned by NTT.

    

    NTT
      shall
      not include any Company Confidential Information in any regulatory application
      or filing; and shall not, except in connection with the registration of patents,
      as set forth in Section 8A below, include any Company Confidential Information
      in any patent application.

    

    
      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

          
          

        

        
          13

          
            

          

        

        
          
          

        

      

    

    

    6.3 Execution
      of Documents.

    

    (a) NTT
      will
      at the expense of the Company execute all documents or instruments or take
      such
      other steps as shall be reasonably necessary to vest in the Company full title
      to all patents in and to the Drug, free and clear of all liens, encumbrances,
      agreements, understandings, requirements of charges, fees, rights, conditions
      or
      restrictions of any kind

    

    b) The
      Company will, at the expense of NTT execute all documents or instruments or
      take
      such other steps as shall be reasonably necessary to vest in NTT full title
      to
      all patents claiming and including the Drug Formulation and Development Results
      free and clear of all liens, encumbrances, agreements, understandings,
      requirements of charges, fees, rights, conditions or restrictions of any
      kind.

    

    6.4 Regulatory
      Applications.
      NTT
      shall provide Company with the information and data relating to the Drug
      Formulation and Product in order to permit Company in the filing and obtaining
      regulatory approval for the Products. If needed, and if applicable NTT shall
      provide the Company with the information and data relating to NTT Formulation
      Technology and a cross reference letter to the NTT Formulation
      Technology.

    

    6.5 United
      States Bankruptcy Code.
      To the
      extent applicable, in the event of the rejection of this Agreement by or on
      behalf of either Party under Section 365 of the United States Bankruptcy Code
      (the "Code"),
      all
      licenses and rights to licenses granted under or pursuant to this Agreement
      by
      one Party to the other are, and shall otherwise be deemed to be, for purposes
      of
      Section 365(n) of the Code, licenses of rights to "intellectual property" as
      defined under Section 101(35A) of the Code The Parties agree that each Party,
      as
      the licensee of such rights under this Agreement, shall retain and may fully
      exercise all of its rights and elections under the Code, and that upon
      commencement of a bankruptcy proceeding by or against either Party under the
      Code, the other Party shall be entitled to a complete duplicate of or complete
      access to (as other Party deems appropriate), any such intellectual property
      and
      all embodiments of such intellectual property. Such intellectual property and
      all embodiments thereof shall be promptly delivered to non-rejecting Party
      (i)
      upon any such commencement of a bankruptcy proceeding upon written request
      therefore by the non-bankrupt Party, unless the bankrupt Party elects to
      continue to perform all of its obligations under this Agreement or (ii) if
      not
      delivered under (i) above, upon the rejection of this Agreement by or on behalf
      of a Party upon written request therefore by the other Party. The foregoing
      provisions of Section 6.5 are without prejudice to any rights the non-bankrupt
      Party may have arising under the Code or other applicable.

    

    
      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

          
          

        

        
          14

          
            

          

        

        
          
          

        

      

    

    

    7. Confidentiality

    

    7.
      1 Confidentiality
      and Non-Use.
      The
      parties warrant and undertake towards each other that during the term of this
      Agreement and subsequent thereto, they shall maintain full and absolute
      confidentiality and shall also be liable for their respective employees and/or
      representatives and/or persons acting on their behalf maintaining Confidential
      Information of the other Party absolute confidentiality, which is in and/or
      comes to their knowledge and/or that of their employees, representatives and/or
      any person acting on their behalf directly in connection with this Agreement.
      The parties undertake not to convey or disclose anything in connection with
      the
      foregoing to any entity. Neither Party may use Confidential Information of
      the
      other Party, without the other Party's prior written consent, except as
      expressly permitted in this Agreement.

    

    7.2 Exceptions.
      The
      obligations contained in Section 7.1 shall not apply to information which (a)
      is
      in the public domain as at the date hereof or to information which hereafter
      comes into the public domain, unless due to a breach of the obligations pursuant
      to this Agreement and as a result thereof the information comes into the public
      domain, or (b) was lawfully in the receiving party's possession or control
      prior
      to the time such information was disclosed to such receiving party by the
      disclosing party to whom the information relates, or (c) such information was
      developed by the receiving party independently of and without reference to
      the
      Confidential Information of the disclosing party, or (d) such information was
      lawfully obtained by the receiving party from a third party under no obligation
      of confidentiality to the party to whom such information relates. Any
      combination of features or disclosures shall not be deemed to fall within the
      foregoing exclusions merely because individual features are published or
      available to the general public or in the rightful possession of the Receiving
      Party unless the combination itself and principle of operation are published
      or
      available to the general public or in the rightful possession of the Receiving
      Party. Without derogating from the Company's obligations and liability
      hereunder, the Company may disclose NTT's Confidential Information in the event
      that such disclosure is necessary for the commercialization of the Product;
      provided that any such disclosure shall be made to the minimum extent required
      and subject to written confidentiality undertakings.

    

    
      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

          
          

        

        
          15

          
            

          

        

        
          
          

        

      

    

    

    7.3 Disclosure
      to Governmental Entities.
      Notwithstanding the obligations in Section 7.1, the Company may disclose the
      other Party's Confidential Information to the extent that such disclosure is
      made: (a) to governmental or other regulatory agencies as required thereby
      in
      order to protect Intellectual Property Rights or to gain or maintain approval
      to
      conduct clinical trials or to market Products under this Agreement; or (b)
      otherwise as required to comply with applicable laws or regulations, or (c)
      is
      required to be disclosed by judicial, regulatory, or administrative process
      or
      agencies; provided that disclosure may be only to the minimal extent reasonably
      necessary to obtain such patents or authorizations or comply with such
      applicable law or regulation, and provided that reasonable steps are taken
      to
      ensure confidential treatment of such Confidential Information (if applicable
      or
      available). The Company will, in (b) and (c) above, provide NTT with prompt
      notice so that it may seek a protective order or other appropriate
      remedy.

    

    In
      the
      event that NTT is requested or become legally compelled (by oral questions,
      interrogatories, requests for information or documents, subpoena, civil
      investigative demand or similar process) to disclose any Confidential
      Information, NTT will provide the Company with prompt notice so that it may
      seek
      a protective order or other appropriate remedy and/or waive compliance with
      the
      provisions of this Agreement. In the event that such protective order or other
      remedy is not obtained, NTT will furnish only that portion of the Confidential
      Information that is legally required Further, Company acknowledges that if
      NTT
      is a public entity that NTT may be legally required to make public disclosures
      (including in filings with the SEC or other agency) of certain material
      developments or material Information generated under this Agreement and agrees
      that Company may make such disclosures as required by law, subject to Company's
      prior written consent to the content of such disclosure, which consent shall
      not
      be unreasonably withheld or delayed.

    

    Confidential
      Information that is disclosed as set forth in this Section 7.3, shall (except
      for registration of patents) remain otherwise subject to the confidentiality
      and
      non-use provisions of this agreement, and the Party disclosing Confidential
      Information pursuant to law or court order shall take all steps reasonably
      necessary, including without limitation obtaining an order of confidentiality,
      to ensure the continued confidential treatment of such Confidential
      Information,

    

    Further,
      NTT acknowledges that Company may be legally required to make public disclosures
      (including in filings with the SEC or other agency) of certain material
      developments or material Information generated under this Agreement and agrees
      that Company may make such disclosures as required by law, subject to NTT's
      prior written consent to the content of such disclosure, which consent shall
      not
      be unreasonably withheld or delayed.

    

    
      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

          
          

        

        
          16

          
            

          

        

        
          
          

        

      

    

    

    7.4 Termination
      of this Agreement.
      The end
      or termination of this Agreement shall not release the parties from their
      obligations pursuant to this section.

    

    8. Representations
      Disclaimers and Warranties.

    

    8.1 Mutual
      Representations.
      Each of
      the Parties hereby represents to the other Party that: The execution and
      delivery of this Agreement and the fulfillment of the terms hereof (i) will
      not
      constitute a default under or conflict with any agreement or other instrument
      to
      which he or it is a party or by which he or it is bound; and (ii) does not
      require third party consents. This Agreement constitutes the valid and binding
      obligation of such party enforceable against such party in accordance with
      its
      terms subject to applicable bankruptcy, insolvency, moratorium and similar
      laws
      affecting creditors' rights generally, and subject, as to enforceability, to
      general principles of equity (regardless if enforcement is sought in a
      proceeding in equity or at law).

    

    8.2 Disclaimers.
      Each
      Party hereby acknowledges that the data and any materials to be provided to
      such
      Party by the other Party under this Agreement will be of an experimental nature,
      provided without warranties, and neither Party shall accept any liability in
      connection with their use by the other Party.

    

    EXCEPT
      AS
      EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION
      OR
      WARRANTY TO THE OTHER PARTY OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING, WITHOUT
      LIMITATION, ANY WARRANTY OF NON-INFRINGEMENT, MERCHANTABILITY OR FITNESS FOR
      A
      PARTICULAR PURPOSE OR NON-INFRINGEMENT. WITHOUT LIMITING THE GENERALITY OF
      THE
      FOREGOING, EACH PARTY ACKNOWLEDGES THAT THIS AGREEMENT PROVIDES FOR AN
      INNOVATIVE PROGRAM USING NEW TECHNOLOGIES AND THAT NO WARRANTY IS MADE REGARDING
      THE SUCCESS OF ANY RESEARCH DONE PURSUANT TO THIS AGREEMENT OR THE UTILITY
      OF
      ANY INFORMATION, MATERIALS OR TECHNOLOGY PROVIDED HEREUNDER. EACH PARTY
      EXPRESSLY DISCLAIMS ALL WARRANTIES AS TO THE VALIDITY OR SCOPE OF PATENTS AND
      PATENT CLAIMS, ISSUED AND PENDING, PROTECTING ITS TECHNOLOGY OR THAT ANY
      TECHNOLOGY WILL BE FREE FROM INFRINGEMENT OF PATENTS OR PROPRIETARY RIGHTS
      OF
      THIRD PARTIES, OR THAT NO THIRD PARTIES ARE IN ANY WAY INFRINGING PATENT
      RIGHTS.

    

    
      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

          
          

        

        
          17

          
            

          

        

        
          
          

        

      

    

    

    8.3. NTT's
      Representations and Warranties.
      NTT
      warrants and represents to the Company that: 

    

    (a) It
      has
      the ability, licenses, experience, and professional staff to perform all its
      duties under this Agreement; the Development Plan shall be performed in a manner
      and with professional diligence and skill; 

    

    (b) It
      has
      all the rights required in order to assign, grant, license, convey and transfer
      any and all applicable rights under this Agreement to the Company, all of which
      are free and clear of any liens, charges and encumbrances, and except for Yissum
      in regard to NTT Patents, no other person, corporate or other private entity,
      or
      governmental entity or subdivision thereof, has or shall have any claim of
      ownership whatsoever;

    

    (c) Any
      and
      all Development Results, Drug Formulation, Products, and any Intellectual
      Property Rights that result from the Development Plan and/or Development Results
      and/or which cover the Drug Formulation and Product under this Agreement
      Resulting Patents are made by NTT, and are not made, conceived or reduced to
      practice by Hebrew University and/or Yissum, or any employee of Hebrew
      University. Hebrew University and/or Yissum will have no rights, tittle, or
      interest in and to the Drug Formulation, Products, and Developmental Plan
      Results, or Intellectual Property Rights that result from the Development Plan
      and/or Development Results and/or which cover the Drug Formulation and Product
      (d) NTT shall not assign, license, convey, transfer or grant rights or title
      to
      any Development Plan Results, and/or Drug Formulation, and/or Product; and/or
      Intellectual Property Rights that result from the Development Plan and/or
      Development Results and/or cover the Drug Formulation and Product to a third
      party. It is hereby clarified that the above provision does not apply to NTT
      Patents.

    

    
      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

          
          

        

        
          18

          
            

          

        

        
          
          

        

      

    

    

    (d) To
      NTT's
      knowledge, there are no claims, judgments or settlements against or owed by
      NTT
      and no pending or threatened claims or litigation relating to the NTT Patents
      covering the NTT Formulation Technology.

    

    8.3 The
      Company's Representations and Warranties.
      The
      Company hereby represents and warrants to NTT that it is the owner of the Drug
      and all Intellectual Property Rights therein and thereto and that NTT's use
      of
      the Drug in the performance of the Development Plan shall not constitute a
      breach of any third party Intellectual Property Rights or other
      rights.

    

    8A. Intellectual
      Property.

    

    8A.l Company
      Option.
      The
      Company has the first and exclusive option ("Option")
      to
      exercise file, prosecute and maintain any Intellectual Property Rights that
      result from the Development Plan and/or Development Results, including Resulting
      Patents and/or disclose and/or claim the Drug Formulation and Product
      ("Prosecute"
      or
      "Prosecution”)
      in the
      Territory. The Company (i) shall give NTT an opportunity to review the text
      of
      the patent documents in a timely manner before filing, and shall supply NTT
      with
      a copy of the patent documents and responses as filed; (ii) shall report and
      provide NTT with all prosecution in a foreign jurisdiction in a timely manner,
      (iii) promptly give notice to NTT of the grant, lapse, revocation, surrender,
      invalidation or abandonment of patents filed under this Agreement. The Company
      shall bear the fees and expenses related to the Prosecution of the patents
      under
      this section 8A.1 covering the Products.

    

    In
      the
      event that Company does not exercise the Option, it shall so notify NTT and
      NTT
      shall

    

    be
      entitled to Prosecute.

    

    8A.2 Interference,
      Opposition, Reexamination and Reissue.
      Each
      Party shall, within ten (10) days of learning of an interference, opposition
      proceeding, or reexamination and/or reissue of one of its patents in and to
      the
      Drug, NTT Formulation Technology, Drug Formulation, Development Results,
      including Resulting Patents and/or Products, inform the other Party of any
      request for, or filing or declaration of, any interference, opposition, reissue
      or reexamination relating to the NTT Patents and Resulting Patents covering
      the
      Products. NTT and the Company shall thereafter consult and cooperate fully
      to
      determine a course of action with respect to any such proceeding and provide
      any
      information or assistance that the Company may reasonably request. The Company
      shall take the lead and have the first, sole and exclusive right to defend,
      respond, prosecute such actions hereunder; provided that no settlement shall
      be
      entered into without NTT's prior written consent which shall not be unreasonable
      withheld.

    

    The
      Company shall bear the expense of any interference, opposition, reexamination,
      or reissue proceeding.

    

      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

          
          

        

        
          19

          
            

          

        

        
          
          

        

      

    8A.3 Enforcement
      and Defense.
      Each
      Party shall, promptly after it becomes aware of such an event, give the other
      Party notice of any infringement of the [NTT and] Resulting Patents and any
      misappropriation or misuse of NTT Formulation Technology or Drug Formulation
      and/or proprietary know-how developed through the Development Plan. NTT and
      the
      Company shall thereafter consult and cooperate fully to determine a course
      of
      action with respect to any such proceeding, and NTT shall provide any
      information or assistance that the Company may reasonably request. The Company
      shall take the lead and have the first, sole and exclusive right to will defend,
      respond, prosecute such actions hereunder; provided that no settlement shall
      be
      entered into without NTT's prior written consent which shall not be unreasonable
      withheld.

    

    9. Liability,
      Indemnity and Insurance

    

    9.1 Indemnification.
      Each of
      the Parties hereby agrees to indemnify, defend, and hold the other Party, its
      officers, employees, and service providers, harmless from and against any
      liability, damages, costs or expenses (including reasonable attorneys' fees)
      resulting from any claim, demand, loss, injury, or liability of any kind or
      nature made or incurred by any third party, as the case may be, arising from
      (a)
      any breach by the indemnifying party of its obligations hereunder (b) the
      falsity or breach of any of the indemnifying party's representations, warranties
      or covenants hereunder, or v) the gross negligence or willful misconduct. In
      addition, (c) NTT will indemnify the Company and hold it harmless from and
      against any claim or action alleging infringement of any patent, trademark,
      copyright or other intellectual property of any third party by the manufacture,
      sale or use of the Drug Formulation; and (d) the Company will indemnify NTT
      and
      hold it harmless from and against any claim or action alleging infringement
      of
      any patent, trademark, copyright or other intellectual property of any third
      party by the use of the Drug.

    

    9.2 Insurance.
      Each
      Party shall obtain and maintain throughout the term of this Agreement, insurance
      policies covering its liabilities hereunder and liabilities resulting from
      this
      Agreement and the performance hereunder, for such insurance amounts as are
      customary in the industry. Upon request from the other Party, each Party shall
      deliver to the other Party a copy of such insurance policies. 

    

      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

          
          

        

        
          20

          
            

          

        

        
          
          

        

      

    

     

    9.3 Limitation
      of Liability.
      UNDER
      NO CIRCUMSTANCES SHALL EITHER PARTY BE LIABLE FOR INCIDENTAL, INDIRECT, SPECIAL
      OR CONSEQUENTIAL DAMAGES (HOWEVER ARISING) OF THE OTHER PARTY AND WHETHER IN
      RESPECT OF DEATH, PERSONAL INJURY, DAMAGES TO OR LOSS OF PROPERTY OR EQUIPMENT,
      INCLUDING, BUT NOT LIMITED TO, LOSS OF PROFIT, LOSS OF USE, LOSS OF REVENUES
      OR
      DAMAGES TO BUSINESS OR REPUTATION ARISING FROM THE PERFORMANCE OR
      NON-PERFORMANCE OF ANY ASPECT OF THIS AGREEMENT OR ANY PURCHASE ORDERS
      THEREUNDER WHETHER OR NOT SUCH PARTY SHALL HAVE BEEN MADE AWARE OF THE
      POSSIBILITY OF SUCH LOSS.

    

    10. Termination
      of the Agreement

    

    10.1 Termination
      due to Cease of Development or Commercialization.
      In the
      event that the Company decides to cease the development and commercialization
      of
      the Product, as set forth in Section 5, it shall promptly provide a notice
      detailing the reasons for termination to NTT, and this Agreement shall
      immediately terminate.

    

    10.2 Material
      Breach.
      Either
      party may terminate this Agreement at any time in the event of a material breach
      by the other party of any of the terms and conditions of this Agreement,
      subject, provided the non breaching party provide a 30 day notice detailed
      the
      nature of the breach and the other party does not cure the breach within 30
      days.

    

    10.3 Termination
      by Either Party.
      Either
      Party may terminate this Agreement upon the occurrence of any of the following
      events: 

    

    If
      a
      receiver or liquidator is appointed for the other Party and/or the other Party
      passes a resolution for voluntary winding up or a winding up application is
      made
      against the other Party and not set aside within 60 days.

    

    (b)
      If an
      attachment is made over the other Party's major assets and/or if execution
      proceedings are taken against other Party and the same are not set aside within
      60 days of the date the attachment is made or the execution proceedings are
      taken.

    

    The
      Party
      undergoing the events described above shall provide a written notice to the
      first Party of the occurrence of such events.

    

    
      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

          
          

        

        
          21

          
            

          

        

        
          
          

        

      

    

    

    10.4 Effects
      of Termination.
      The
      following provisions shall apply upon termination of this Agreement for any
      reason:

    

    (a)
      The
      provisions regarding confidentiality, non-use, and ownership, indemnification,
      and insurance shall survive or termination of this Agreement howsoever caused.
      Notwithstanding the aforesaid, the end or termination of this Agreement shall
      not release the Company from its financial obligation incurred prior to the
      Agreement's end or termination.

    

    (b)
      Each
      Party shall, within 14 days after such termination, return to the other Party
      or
      destroy (which destruction shall he accompanied by a declaration of the CEO
      of
      Party, confirming such destruction) all Confidential Information and any
      proprietary materials, information, databases and records, accounts, notes,
      reports and data of the other Party, without maintain any copies thereof or
      containing Confidential Information of the other Party.

    

    11. Relationship
      between the Parties.

    

    It
      is
      hereby agreed and declared between the parties that they shall act in all
      respects relating to this Agreement as an independent contractor and there
      neither is nor shall be agent relationship and/or partnership in the
      relationship between them.

    

    12.
      Law

    

    The
      provisions of this Agreement and everything concerning the relationship between
      the parties in accordance with this Agreement shall be governed solely by
      Israeli law and both Parties consent to exclusive jurisdiction by the competent
      courts of the Tel Aviv-Jaffa district.

    

    13.
      Miscellaneous

    

    13.1 Assignment.
      The
      Parties may not transfer and/or assign and/or endorse their rights and/or duties
      and/or any of them pursuant to this Agreement to another.

    

    13.2 Binding
      Effect. This
      Agreement and all rights and obligations hereunder shall inure to the benefit
      of
      and be binding upon the Parties, their Affiliates, and their respective lawful
      successors and assigns (including, without limitation, any successor to a Party
      upon a Change of Control).

    

    13.3 Waiver.
      The
      failure or delay of a Party to the Agreement to claim the performance of an
      obligation of the other Party shall not be deemed a waiver of the performance
      of
      such obligation.

    

    
      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

          
          

        

        
          22

          
            

          

        

        
          
          

        

      

    

    

    13.4 Full
      Agreement.
      This
      Agreement constitutes a full and complete Agreement between the Parties with
      respect to the subject matter hereof, and may only be amended by a document
      signed by both parties. 

    

    13.5 Notices.
      All
      notices and communications pursuant to this Agreement shall be made in writing
      and sent to or served at the following addresses:

     

    
      	
              NTT:

            	
              Novel
                Therapeutic Technologies Inc.

            
	 	
              POB
                12006,

            
	 	
              7
                Yad Harutzim

            
	 	
              Herzliya
                Pituach 46722

            
	 	
              ISRAEL

            
	 	
              Tel
                - 972-9-961-2703

            
	 	
              Fax
                - 972-9-961-2701

            
	 	 
	
              Attention
                Dan Touitou

            
	 	 
	
              With
                a copy to: Gross, Kleinhendler, Hodak, Berkman & Co. Law
                Offices

            
	 	
              One
                Azrieli Center (Round Building)

            
	 	
              Tel
                Aviv 67021, Israel

            
	 	
              Tel:
                +972-3-6074520

            
	 	
              Fax:
                +972-3-6074411

            
	 	 
	 	
              Attention:
                Adv. Heather A. Stone

            
	 	 
	
              The
                Company:-

            
	 	 
	 	
              Synvista
                Therapeutics, Inc.

            
	 	
              221
                West Grand Avenue, Suite 200

            
	 	
              Montvale,
                New Jersey 07645

            
	 	
              Tel:
                201-818-5000

            
	 	
              Fax:
                201-934-8880

            
	 	 
	 	
              Attention:
                Dr. Noah Berkowitz

            
	
              With
                a copy to

            
	 	 
	 	
              Pearl
                Cohen Zedek Latzer, LLP

            
	 	
              1500
                Broadway, 12th Floor

            
	 	
              New
                York, NY 10036

            
	 	
              Tel:
                646-878-0804

            
	 	
              Fax:
                646-878-0801

            
	 	 
	 	
              Attention:
                Mark S. Cohen

            

    

    

    
      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

          
          

        

        
          23

          
            

          

        

        
          
          

        

      

    

    

    or
      such
      other address furnished in writing by one party to the other. If the notice
      is
      sent by registered mail, it shall be deemed to have been received seven days
      after being posted by registered mail, if by facsimile, within one business
      day
      and if in person, upon actual delivery.

    

    IN
      WITNESS THE HANDS OF THE PARTIES

    

    
      	
              NTT

            	 	 	
              THE
                COMPANY

            
	 	 	 	 	 
	
              By:

            	
              
                /s/
                  Dan Touitou

              

            	 	
              By:

            	/s/
              Noah Berkowitz
	 	 	 	 	 
	
              Name:

            	
              Dan
                Touitou

            	 	
              Name:

            	Noah
              Berkowitz, MD, PhD
	 	 	 	 	 
	
              Title:

            	
              CEO

            	 	
              Title:

            	President
              & CEO
	 	 	 	 	 
	
              Date:

            	
              January
                20, 2008

            	 	
              Date:

            	
              January
                20, 2008

            

    

    

    
      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

          
          

        

        
          24

          
            

          

        

        
          
          

        

      

    

    

    Exhibit
      A

    

    Development
      Plan

    

    
      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

          
          

        

        
          25

          
            

          

        

        
          
          

        

      

    

    
      

      
        Portions
          of this Exhibit were omitted and have been
          filed separately with the Secretary of the Commission pursuant to the Company’s
          application requesting confidential treatment under Rule 24b-2 of the Securities
          Exchange Act of 1934.

      

      
        
          
          

        

        
          26

          
            

          

        

        
          
          

        

      

    

    

    Exhibit
      B

    

    
      The
        Drug

    

    

      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

          
          

        

        
          27

          
            

          

        

        
          
          

        

      

    

    
      

        
          	
                  Provid
                    Number

                	
                  Lab
                    Journal Reference

                	
                  Molecular
                    Formula

                	
                  Molecular
                    Weight

                	
                  Structure

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                

        

      

       

      Portions
        of this Exhibit were omitted and have been
        filed separately with the Secretary of the Commission pursuant to the Company’s
        application requesting confidential treatment under Rule 24b-2 of the Securities
        Exchange Act of 1934.

      
        
        

      

      
        28

        
          

        

      

      
        
        

      

    

    
      

        
          	
                  Provid
                    Number

                	
                  Lab
                    Journal Reference

                	
                  Molecular
                    Formula

                	
                  Molecular
                    Weight

                	
                  Structure

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                

        

      

       

      Portions
        of this Exhibit were omitted and have been
        filed separately with the Secretary of the Commission pursuant to the Company’s
        application requesting confidential treatment under Rule 24b-2 of the Securities
        Exchange Act of 1934.

    

    
      
        
        

      

      
        29

        
          

        

      

      
        
        

      

      
        

          
            	
                    Provid
                      Number

                  	
                    Lab
                      Journal Reference

                  	
                    Molecular
                      Formula

                  	
                    Molecular
                      Weight

                  	
                    Structure

                  
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                    [***]

                  	
                    [***]

                  	
                    [***]

                  	
                    [***]

                  	
                    [***]

                  
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                    [***]

                  	
                    [***]

                  	
                    [***]

                  	
                    [***]

                  	
                    [***]

                  

          

        

         

        Portions
          of this Exhibit were omitted and have been
          filed separately with the Secretary of the Commission pursuant to the Company’s
          application requesting confidential treatment under Rule 24b-2 of the Securities
          Exchange Act of 1934.

      

    

    
      
        
        

      

      
        30

        
          

        

      

      
        
        

      

    

    
      

        
          	
                  Provid
                    Number

                	
                  Lab
                    Journal Reference

                	
                  Molecular
                    Formula

                	
                  Molecular
                    Weight

                	
                  Structure

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                

        

      

       

      Portions
        of this Exhibit were omitted and have been
        filed separately with the Secretary of the Commission pursuant to the Company’s
        application requesting confidential treatment under Rule 24b-2 of the Securities
        Exchange Act of 1934.

    

    
      
        
        

      

      
        31

        
          

        

      

      
        
        

      

    

    
      

        
          	
                  Provid
                    Number

                	
                  Lab
                    Journal Reference

                	
                  Molecular
                    Formula

                	
                  Molecular
                    Weight

                	
                  Structure

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                

        

      

       

      Portions
        of this Exhibit were omitted and have been
        filed separately with the Secretary of the Commission pursuant to the Company’s
        application requesting confidential treatment under Rule 24b-2 of the Securities
        Exchange Act of 1934.

    

    
      
        
        

      

      
        32

        
          

        

      

      
        
        

      

    

    
      

        
          	
                  Provid
                    Number

                	
                  Lab
                    Journal Reference

                	
                  Molecular
                    Formula

                	
                  Molecular
                    Weight

                	
                  Structure

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                

        

      

       

      Portions
        of this Exhibit were omitted and have been
        filed separately with the Secretary of the Commission pursuant to the Company’s
        application requesting confidential treatment under Rule 24b-2 of the Securities
        Exchange Act of 1934.

    

    
      
        
        

      

      
        33

        
          

        

      

      
        
        

      

    

    
      

        
          	
                  Provid
                    Number

                	
                  Lab
                    Journal Reference

                	
                  Molecular
                    Formula

                	
                  Molecular
                    Weight

                	
                  Structure

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                

        

      

       

      Portions
        of this Exhibit were omitted and have been
        filed separately with the Secretary of the Commission pursuant to the Company’s
        application requesting confidential treatment under Rule 24b-2 of the Securities
        Exchange Act of 1934.

    

    
      
        
          
          

        

        
          34

          
            

          

        

        
          
          

        

      

      

        
          	
                  Provid
                    Number

                	
                  Lab
                    Journal Reference

                	
                  Molecular
                    Formula

                	
                  Molecular
                    Weight

                	
                  Structure

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                

        

      

       

      Portions
        of this Exhibit were omitted and have been
        filed separately with the Secretary of the Commission pursuant to the Company’s
        application requesting confidential treatment under Rule 24b-2 of the Securities
        Exchange Act of 1934.

    

    
      
        
          
          

        

        
          35

          
            

          

        

        
          
          

        

      

      

        
          	
                  Provid
                    Number

                	
                  Lab
                    Journal Reference

                	
                  Molecular
                    Formula

                	
                  Molecular
                    Weight

                	
                  Structure

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                

        

      

       

      Portions
        of this Exhibit were omitted and have been
        filed separately with the Secretary of the Commission pursuant to the Company’s
        application requesting confidential treatment under Rule 24b-2 of the Securities
        Exchange Act of 1934.

    

    
      
        
          
          

        

        
          36

          
            

          

        

        
          
          

        

      

      

        
          	
                  Provid
                    Number

                	
                  Lab
                    Journal Reference

                	
                  Molecular
                    Formula

                	
                  Molecular
                    Weight

                	
                  Structure

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                

        

      

       

      Portions
        of this Exhibit were omitted and have been
        filed separately with the Secretary of the Commission pursuant to the Company’s
        application requesting confidential treatment under Rule 24b-2 of the Securities
        Exchange Act of 1934.

    

    
      
        
          
          

        

        
          37

          
            

          

        

        
          
          

        

      

      

        
          	
                  Provid
                    Number

                	
                  Lab
                    Journal Reference

                	
                  Molecular
                    Formula

                	
                  Molecular
                    Weight

                	
                  Structure

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                

        

      

       

      Portions
        of this Exhibit were omitted and have been
        filed separately with the Secretary of the Commission pursuant to the Company’s
        application requesting confidential treatment under Rule 24b-2 of the Securities
        Exchange Act of 1934.

    

    
      
        
          
          

        

        
          38

          
            

          

        

        
          
          

        

      

      

        
          	
                  Provid
                    Number

                	
                  Lab
                    Journal Reference

                	
                  Molecular
                    Formula

                	
                  Molecular
                    Weight

                	
                  Structure

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                

        

      

       

      Portions
        of this Exhibit were omitted and have been
        filed separately with the Secretary of the Commission pursuant to the Company’s
        application requesting confidential treatment under Rule 24b-2 of the Securities
        Exchange Act of 1934.

    

    
      
        
          
          

        

        
          39

          
            

          

        

        
          
          

        

      

      

        
          	
                  Provid
                    Number

                	
                  Lab
                    Journal Reference

                	
                  Molecular
                    Formula

                	
                  Molecular
                    Weight

                	
                  Structure

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                

        

      

       

      Portions
        of this Exhibit were omitted and have been
        filed separately with the Secretary of the Commission pursuant to the Company’s
        application requesting confidential treatment under Rule 24b-2 of the Securities
        Exchange Act of 1934.

    

    
      
        
          
          

        

        
          40

          
            

          

        

        
          
          

        

      

      

        
          	
                  Provid
                    Number

                	
                  Lab
                    Journal Reference

                	
                  Molecular
                    Formula

                	
                  Molecular
                    Weight

                	
                  Structure

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                

        

      

       

      Portions
        of this Exhibit were omitted and have been
        filed separately with the Secretary of the Commission pursuant to the Company’s
        application requesting confidential treatment under Rule 24b-2 of the Securities
        Exchange Act of 1934.

    

    
      
        
          
          

        

        
          41

          
            

          

        

        
          
          

        

      

      

        
          	
                  Provid
                    Number

                	
                  Lab
                    Journal Reference

                	
                  Molecular
                    Formula

                	
                  Molecular
                    Weight

                	
                  Structure

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                

        

      

       

      Portions
        of this Exhibit were omitted and have been
        filed separately with the Secretary of the Commission pursuant to the Company’s
        application requesting confidential treatment under Rule 24b-2 of the Securities
        Exchange Act of 1934.

    

    
      
        
          
          

        

        
          42

          
            

          

        

        
          
          

        

      

      

        
          	
                  Provid
                    Number

                	
                  Lab
                    Journal Reference

                	
                  Molecular
                    Formula

                	
                  Molecular
                    Weight

                	
                  Structure

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                

        

      

       

      Portions
        of this Exhibit were omitted and have been
        filed separately with the Secretary of the Commission pursuant to the Company’s
        application requesting confidential treatment under Rule 24b-2 of the Securities
        Exchange Act of 1934.

    

    
      
        
          
          

        

        
          43

          
            

          

        

        
          
          

        

      

      

        
          	
                  Provid
                    Number

                	
                  Lab
                    Journal Reference

                	
                  Molecular
                    Formula

                	
                  Molecular
                    Weight

                	
                  Structure

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                

        

      

       

      Portions
        of this Exhibit were omitted and have been
        filed separately with the Secretary of the Commission pursuant to the Company’s
        application requesting confidential treatment under Rule 24b-2 of the Securities
        Exchange Act of 1934.

    

    
      
        
          
          

        

        
          44

          
            

          

        

        
          
          

        

      

      

        
          	
                  Provid
                    Number

                	
                  Lab
                    Journal Reference

                	
                  Molecular
                    Formula

                	
                  Molecular
                    Weight

                	
                  Structure

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                

        

      

       

      Portions
        of this Exhibit were omitted and have been
        filed separately with the Secretary of the Commission pursuant to the Company’s
        application requesting confidential treatment under Rule 24b-2 of the Securities
        Exchange Act of 1934.

    

    
      
        
          
          

        

        
          45

          
            

          

        

        
          
          

        

      

      

        
          	
                  Provid
                    Number

                	
                  Lab
                    Journal Reference

                	
                  Molecular
                    Formula

                	
                  Molecular
                    Weight

                	
                  Structure

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                

        

      

       

      Portions
        of this Exhibit were omitted and have been
        filed separately with the Secretary of the Commission pursuant to the Company’s
        application requesting confidential treatment under Rule 24b-2 of the Securities
        Exchange Act of 1934.

    

    
      
        
          
          

        

        
          46

          
            

          

        

        
          
          

        

      

      

        
          	
                  Provid
                    Number

                	
                  Lab
                    Journal Reference

                	
                  Molecular
                    Formula

                	
                  Molecular
                    Weight

                	
                  Structure

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                

        

      

       

      Portions
        of this Exhibit were omitted and have been
        filed separately with the Secretary of the Commission pursuant to the Company’s
        application requesting confidential treatment under Rule 24b-2 of the Securities
        Exchange Act of 1934.

    

    
      
        
          
          

        

        
          47

          
            

          

        

        
          
          

        

      

      

        
          	
                  Provid
                    Number

                	
                  Lab
                    Journal Reference

                	
                  Molecular
                    Formula

                	
                  Molecular
                    Weight

                	
                  Structure

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                

        

      

       

      Portions
        of this Exhibit were omitted and have been
        filed separately with the Secretary of the Commission pursuant to the Company’s
        application requesting confidential treatment under Rule 24b-2 of the Securities
        Exchange Act of 1934.

    

    
      
        
          
          

        

        
          48

          
            

          

        

        
          
          

        

      

      

        
          	
                  Provid
                    Number

                	
                  Lab
                    Journal Reference

                	
                  Molecular
                    Formula

                	
                  Molecular
                    Weight

                	
                  Structure

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                

        

      

       

      Portions
        of this Exhibit were omitted and have been
        filed separately with the Secretary of the Commission pursuant to the Company’s
        application requesting confidential treatment under Rule 24b-2 of the Securities
        Exchange Act of 1934.

    

    
      
        
          
          

        

        
          49

          
            

          

        

        
          
          

        

      

      

        
          	
                  Provid
                    Number

                	
                  Lab
                    Journal Reference

                	
                  Molecular
                    Formula

                	
                  Molecular
                    Weight

                	
                  Structure

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                

        

      

       

      Portions
        of this Exhibit were omitted and have been
        filed separately with the Secretary of the Commission pursuant to the Company’s
        application requesting confidential treatment under Rule 24b-2 of the Securities
        Exchange Act of 1934.

    

    
      
        
          
          

        

        
          50

          
            

          

        

        
          
          

        

      

    

    
      

        
          	
                  Provid
                    Number

                	
                  Lab
                    Journal Reference

                	
                  Molecular
                    Formula

                	
                  Molecular
                    Weight

                	
                  Structure

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                

        

      

       

      Portions
        of this Exhibit were omitted and have been
        filed separately with the Secretary of the Commission pursuant to the Company’s
        application requesting confidential treatment under Rule 24b-2 of the Securities
        Exchange Act of 1934.

    

    
      
        
          
          

        

        
          51

          
            

          

        

        
          
          

        

      

      

        
          	
                  Provid
                    Number

                	
                  Lab
                    Journal Reference

                	
                  Molecular
                    Formula

                	
                  Molecular
                    Weight

                	
                  Structure

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                

        

      

       

      Portions
        of this Exhibit were omitted and have been
        filed separately with the Secretary of the Commission pursuant to the Company’s
        application requesting confidential treatment under Rule 24b-2 of the Securities
        Exchange Act of 1934.

    

    
      
        
          
          

        

        
          52

          
            

          

        

        
          
          

        

      

      

        
          	
                  Provid
                    Number

                	
                  Lab
                    Journal Reference

                	
                  Molecular
                    Formula

                	
                  Molecular
                    Weight

                	
                  Structure

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                

        

      

       

      Portions
        of this Exhibit were omitted and have been
        filed separately with the Secretary of the Commission pursuant to the Company’s
        application requesting confidential treatment under Rule 24b-2 of the Securities
        Exchange Act of 1934.

    

    
      
        
          
          

        

        
          53

          
            

          

        

        
          
          

        

      

      

        
          	
                  Provid
                    Number

                	
                  Lab
                    Journal Reference

                	
                  Molecular
                    Formula

                	
                  Molecular
                    Weight

                	
                  Structure

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                

        

      

       

      Portions
        of this Exhibit were omitted and have been
        filed separately with the Secretary of the Commission pursuant to the Company’s
        application requesting confidential treatment under Rule 24b-2 of the Securities
        Exchange Act of 1934.

    

    
      
        
          
          

        

        
          54

          
            

          

        

        
          
          

        

      

    

    
      

        
          	
                  Provid
                    Number

                	
                  Lab
                    Journal Reference

                	
                  Molecular
                    Formula

                	
                  Molecular
                    Weight

                	
                  Structure

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                

        

      

       

      Portions
        of this Exhibit were omitted and have been
        filed separately with the Secretary of the Commission pursuant to the Company’s
        application requesting confidential treatment under Rule 24b-2 of the Securities
        Exchange Act of 1934.

    

    
      
        
          
          

        

        
          55

          
            

          

        

        
          
          

        

      

    

    
      

        
          	
                  Provid
                    Number

                	
                  Lab
                    Journal Reference

                	
                  Molecular
                    Formula

                	
                  Molecular
                    Weight

                	
                  Structure

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                

        

      

       

      Portions
        of this Exhibit were omitted and have been
        filed separately with the Secretary of the Commission pursuant to the Company’s
        application requesting confidential treatment under Rule 24b-2 of the Securities
        Exchange Act of 1934.

    

    
      
        
          
          

        

        
          56

          
            

          

        

        
          
          

        

      

    

    
      

        
          	
                  Provid
                    Number

                	
                  Lab
                    Journal Reference

                	
                  Molecular
                    Formula

                	
                  Molecular
                    Weight

                	
                  Structure

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                

        

      

       

      Portions
        of this Exhibit were omitted and have been
        filed separately with the Secretary of the Commission pursuant to the Company’s
        application requesting confidential treatment under Rule 24b-2 of the Securities
        Exchange Act of 1934.

    

    
      
        
          
          

        

        
          57

          
            

          

        

        
          
          

        

      

    

    
      

        
          	
                  Provid
                    Number

                	
                  Lab
                    Journal Reference

                	
                  Molecular
                    Formula

                	
                  Molecular
                    Weight

                	
                  Structure

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                

        

      

       

      Portions
        of this Exhibit were omitted and have been
        filed separately with the Secretary of the Commission pursuant to the Company’s
        application requesting confidential treatment under Rule 24b-2 of the Securities
        Exchange Act of 1934.

    

    
      
        
          
          

        

        
          58

          
            

          

        

        
          
          

        

      

    

    
      

        
          	
                  Provid
                    Number

                	
                  Lab
                    Journal Reference

                	
                  Molecular
                    Formula

                	
                  Molecular
                    Weight

                	
                  Structure

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                

        

      

       

      Portions
        of this Exhibit were omitted and have been
        filed separately with the Secretary of the Commission pursuant to the Company’s
        application requesting confidential treatment under Rule 24b-2 of the Securities
        Exchange Act of 1934.

    

    
      
        
          
          

        

        
          59

          
            

          

        

        
          
          

        

      

    

    
      

        
          	
                  Provid
                    Number

                	
                  Lab
                    Journal Reference

                	
                  Molecular
                    Formula

                	
                  Molecular
                    Weight

                	
                  Structure

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                

        

      

       

      Portions
        of this Exhibit were omitted and have been
        filed separately with the Secretary of the Commission pursuant to the Company’s
        application requesting confidential treatment under Rule 24b-2 of the Securities
        Exchange Act of 1934.

    

    
      
        
          
          

        

        
          60

          
            

          

        

        
          
          

        

      

    

    
      

        
          	
                  Provid
                    Number

                	
                  Lab
                    Journal Reference

                	
                  Molecular
                    Formula

                	
                  Molecular
                    Weight

                	
                  Structure

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                

        

      

       

      Portions
        of this Exhibit were omitted and have been
        filed separately with the Secretary of the Commission pursuant to the Company’s
        application requesting confidential treatment under Rule 24b-2 of the Securities
        Exchange Act of 1934.

    

    
      
        
          
          

        

        
          61

          
            

          

        

        
          
          

        

        
          

            
              	
                      Provid
                        Number

                    	
                      Lab
                        Journal Reference

                    	
                      Molecular
                        Formula

                    	
                      Molecular
                        Weight

                    	
                      Structure

                    
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                      [***]

                    	
                      [***]

                    	
                      [***]

                    	
                      [***]

                    	
                      [***]

                    
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                      [***]

                    	
                      [***]

                    	
                      [***]

                    	
                      [***]

                    	
                      [***]

                    

            

          

           

          Portions
            of this Exhibit were omitted and have been
            filed separately with the Secretary of the Commission pursuant to the
            Company’s
            application requesting confidential treatment under Rule 24b-2 of the
            Securities
            Exchange Act of 1934.

        

         

        
          
            
            

          

          
            62

            
              

            

          

          
            
            

          

        

      

    

    
      

        
          	
                  Provid
                    Number

                	
                  Lab
                    Journal Reference

                	
                  Molecular
                    Formula

                	
                  Molecular
                    Weight

                	
                  Structure

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                

        

      

       

      Portions
        of this Exhibit were omitted and have been
        filed separately with the Secretary of the Commission pursuant to the Company’s
        application requesting confidential treatment under Rule 24b-2 of the Securities
        Exchange Act of 1934.

    

    
      
        
          
          

        

        
          63

          
            

          

        

        
          
          

        

      

    

    
      

        
          	
                  Provid
                    Number

                	
                  Lab
                    Journal Reference

                	
                  Molecular
                    Formula

                	
                  Molecular
                    Weight

                	
                  Structure

                
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                

        

      

       

      Portions
        of this Exhibit were omitted and have been
        filed separately with the Secretary of the Commission pursuant to the Company’s
        application requesting confidential treatment under Rule 24b-2 of the Securities
        Exchange Act of 1934.

    

    
      
        
          
          

        

        
          64

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00142-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00142-of-00352.parquet"}]]